Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition [Phase 2, Phase 3]
The update notes ongoing recruitment for the DETERMINE trial Arm 02 investigating atezolizumab in adults and pediatric/young adult patients …
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. [Phase 2, Phase 3]
Phase 2/3 DETERMINE trial treatment arm 05 is evaluating the combination of vemurafenib and cobimetinib in adults with BRAF-positive cancers…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors [Phase 1]
Phase 1 study evaluating CFT1946 as monotherapy and in combination for BRAF V600-mutant solid tumors to assess safety, tolerability, and pre…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating APX005M in combination with pembrolizumab for metastatic melanoma has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma [Phase 2]
Phase 2 trial of intratumoral LTX-315 in combination with pembrolizumab for advanced melanoma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Tracing Dissemination of Melanoma Cells in Healthy Tissues
A completed clinical trial investigating the dissemination of melanoma cells into healthy tissues. The study is sponsored by Assistance Publ…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma [Phase 1, Phase 2]
This document updates on a Phase 1/2 clinical trial assessing different doses of BI-1607 in combination with pembrolizumab and ipilimumab fo…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies [NA]
A clinical trial is evaluating high dose-rate brachytherapy for unresectable primary and metastatic liver malignancies. The study is current…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies [Phase 1]
This clinical trial update notes the termination of a Phase 1 study of BDC-3042 as a single agent and in combination with cemiplimab in pati…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Real-world outcomes in melanoma patients treated with neoadjuvant nivolumab+relatlimab versus nivolumab+ipilimumab; the study is completed a…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer [Phase 1, Phase 2]
This document details an ongoing Phase 1/2 clinical trial evaluating cobolimab in combination with dostarlimab in pediatric and young adult …
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab [Phase 2]
A Phase 2 melanoma trial is investigating adjuvant treatment decisions based on pathological response to neoadjuvant nivolumab. The study in…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) [Phase 1]
Phase 1 study evaluating APX005M in combination with nivolumab and ipilimumab in treatment-naïve patients with advanced melanoma or renal ce…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma [Phase 1, Phase 2]
Update on safety results from a combination therapy using an adenovirus vector engineered to express hIL-12 with an Activator Ligand in mela…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors [Phase 2]
A Phase 2 trial evaluating niraparib in patients with advanced PALB2-mutated tumors was terminated; results have been posted for multiple so…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) [Phase 1, Phase 2]
Phase 1/2 substudy evaluating pembrolizumab alone or with investigational agents in melanoma brain metastases has completed. The update high…
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) [Phase 1, Phase 2]
This update covers a Phase 1/2 trial of pembrolizumab, alone or with investigational agents, in Stage III melanoma patients eligible for neo…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors [Phase 1, Phase 2]
Results from a Phase 1/2 study of E7386 in combination with pembrolizumab in previously treated solid tumors (melanoma, hepatocellular carci…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients [Phase 3]
A Phase 3 study evaluating a melanoma vaccine in stage IIb, IIc, and III melanoma has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: Taxoprexin® Treatment for Advanced Eye Melanoma [Phase 2]
Phase 2 trial update reports completion of Taxoprexin studies for advanced eye melanoma; the excerpt does not include efficacy or safety res…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors [Phase 1]
The Phase 1 trial of HFB301001 in adults with advanced solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: High-Risk Skin Cancers With Atezolizumab Plus NT-I7 [Phase 1, Phase 2]
A terminated Phase 1/2 trial evaluating the combination of atezolizumab and NT-I7 for high-risk skin cancers (melanoma, Merkel cell carcinom…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma [Phase 2]
Phase 2 neoadjuvant trial comparing dostarlimab alone vs cobolimab plus dostarlimab in melanoma is currently active but not recruiting. The …
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors [Phase 1]
This Phase 1 trial update reports on the combination of MGC018 and MGD019 in participants with advanced solid tumors, including castration-r…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies [Phase 1, Phase 2]
Incyte reports a completed phase 1/2 trial evaluating a three-drug immunotherapy combo (INCMGA00012 anti-PD-1, INCAGN02385 anti-LAG-3, INCAG…